alexa Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers.
Materials Science

Materials Science

Journal of Nanomedicine & Biotherapeutic Discovery

Author(s): Garanger E, Boturyn D, Dumy P

Abstract Share this page

Abstract Development of molecular devices endowed with tumor-targeting functions and carrying cytotoxic components should enable the specific delivery of chemotherapeutics to malignant tissues, thus increasing their local efficacy while limiting their peripheral toxicity. Such molecular vectors can pave the way for the development of new classes of therapeutics, fighting against protagonists of neoplastic development. In line with this concept, peptide ligands containing the Arginine-Glycine-Aspartate (RGD) triad, which display a strong affinity and selectivity to the alpha(V)beta(3) integrin, have been developed to target the tumor-associated cells expressing the alpha (V)beta (3) receptors. Among the validated ligands, the leader compound is the cyclic pentapeptide c[-RGDf(NMe)V-] (Cilengitide) developed by kessler et al. (J. Med. Chem., 1999, 42, 3033-3040). This compound has entered phase II clinical trials as an anti-angiogenic agent. Further studies have been directed to develop molecular conjugates of the parent c[-RGDfK-] with conventional chemotherapeutics or with labels for non-invasive imaging technologies. More recently, multimeric RGD containing compounds have been exploited to improve the targeting potential as well as cell-membrane breaching, through receptor-mediated endocytosis. The latter have been constructed on various scaffolds (polylysines or polyglutamates, liposomes, nanoparticles...). Our group has developed a chemical system combining all these properties where multivalent RGD targeting functions are associated with functional molecules through a cyclopeptide template. The latter represents a relevant non-viral vector for tumor targeting, imaging and therapy. This review describes the considerations for the design of the diverse RGD ligands developed so far and reports an overview of the main applications of these structures in cancer research.
This article was published in Anticancer Agents Med Chem and referenced in Journal of Nanomedicine & Biotherapeutic Discovery

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • World Congress on Regulations of Nanotechnology
    July 31-August 01, 2017 Chicago, Illinois, USA
  • 19th Nano Congress for Next Generation
    August 31-September 01, 2017 Brussels,Belgium
  • International conference on Industrial Nanotechnology
    September 18-19, 2017 Jacksonville, Florida, USA
  • 15th World Medical Nanotechnology Congress & Expo
    October 18-19, 2017 Osaka, Japan
  • 22ndInternational Conference and Expo on Nanoscience and Molecular Nanotechnology
    Nov 13-14, 2017 Vienna, Austria
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version